Researchers at the University of Texas Medical Branch at Galveston Graduate Program in Public Health attempted to test the use of two blood markers, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), in monitoring treatment of the degenerative bone disease osteomyelitis in the diabetic foot. 150 patients with diabetic foot osteomyelitis (DFO) were included in the study. Patients were broken into groups (remission and no remission) based on whether the wounds associated with their DFO healed and did not recur. The followup period in which they were monitored was 12 month. The blood markers were also tracked for this time period. After applying inclusion/exclusion criteria, the study included 122 subjects. Factors associated with DFO remission (n = 46) were a lower immune response at admission and improved kidney function. The trajectories of the inflammatory markers over the followup period seemed to show an association between stable values of ESR and CRP and poor clinical outcomes. The trajectories of both ESR and CRP during 12 months follow-up suggest that both markers inflammatory markers may be useful predictive tools when monitoring treatment of DFO.
“Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis” was published in the January edition of International Wound Journal.